Mayo Clinic Health System
Albert Lea, MN
Accepting patients
Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- CLK Inhibitor
- Phase 1/2
Accepting patients